BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$61.93 USD
+1.62 (2.69%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $61.92 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BMRN 61.93 +1.62(2.69%)
Will BMRN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
Other News for BMRN
BMRN Makes Bullish Cross Above Critical Moving Average
UBS Updates Its Analyst Rating and Target Price for BMRN | BMRN Stock News
UBS Adjusts Price Target for BioMarin (BMRN) to $114
BioMarin price target raised by $1 at UBS
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401